- The FDA approves AstraZeneca (AZN +0.3%) and Bristol-Myers Squibb's (BMY +1.2%) Farxiga (dapaglifozin).
- The drug is intended to improve glycemic control in adults with Type 2 diabetes.
- Farxiga isn't recommended for patients with active bladder cancer and the regulator is "requiring six post-marketing studies," including a CVOT.
- FDA PR
From other sites
Video at CNBC.com (Feb 11, 2015)
at CNBC.com (Feb 5, 2015)
at CNBC.com (Jan 14, 2015)
at CNBC.com (Jan 8, 2015)
at CNBC.com (Dec 29, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs